Taberner D A, Poller L, Burslem R W, Jones J B
Br Med J. 1978 Feb 4;1(6108):272-4. doi: 10.1136/bmj.1.6108.272.
The British comparative thromboplastin (BCT) was used to monitor the effectiveness of oral anticoagulants in preventing deep vein thrombosis (DVT) in patients undergoing major gynaecological surgery. All patients were screened for DVT with the use of the (125)I-fibrinogen scan.One hundred and forty-five patients aged 40 years or more were randomised into three groups. Group 1 received oral anticoagulant (nicoumalone) treatment, stabilised over five days before surgery and continuing into the second postoperative week. The other patients served as two contrast groups and were managed on a double-blind basis. Group 2 received a subcutaneous low-dose regimen of heparin calcium. Group 3 received subcutaneous saline. Eleven of 48 patients in the saline group, three of 49 patients in the heparin group, and three of 48 patients in the oral anticoagulant group developed DVT as judged by (125)I-fibrinogen scanning. The incidences in groups 1 and 2 were significantly lower than in the saline group. The falls in haemoglobin concentration and incidence of haemorrhage were similar in all three groups.The study showed that oral anticoagulant prophylaxis stabilised preoperatively and low-dose heparin were equally effective in preventing deep vein thrombosis in a moderate-risk group. Immediate preoperative prothrombin ratios of 2.0-2.5 and postoperative ratios of 2.0-4.0 with the BCT gave adequate protection without increased haemorrhagic risk.
采用英国比较凝血活酶原(BCT)来监测口服抗凝剂在预防接受大型妇科手术患者深静脉血栓形成(DVT)方面的有效性。所有患者均使用(125)I-纤维蛋白原扫描筛查DVT。145名年龄在40岁及以上的患者被随机分为三组。第1组接受口服抗凝剂(尼可香豆素)治疗,术前5天稳定剂量并持续至术后第二周。其他患者作为两个对照组,采用双盲方式管理。第2组接受皮下低剂量肝素钙方案。第3组接受皮下注射生理盐水。根据(125)I-纤维蛋白原扫描判断,生理盐水组48例患者中有11例发生DVT,肝素组49例患者中有3例发生DVT,口服抗凝剂组48例患者中有3例发生DVT。第1组和第2组的发生率显著低于生理盐水组。三组血红蛋白浓度下降和出血发生率相似。该研究表明,术前稳定剂量的口服抗凝剂预防和低剂量肝素在预防中度风险组深静脉血栓形成方面同样有效。使用BCT时,术前凝血酶原比值立即达到2.0 - 2.5,术后比值达到2.0 - 4.0可提供足够的保护,且不会增加出血风险。